Waikato free whooping cough boosters

Friday, 14 September 2012

The special whooping cough vaccine programme for pregnant women from 20 weeks gestation and new mothers up to two weeks after delivery ended on 30 September 2013.

From 1 October 2013 pregnant women in the Waikato District Health Board area can only receive a free Boostrix® between 28-38 weeks of pregnancy through their local doctor.

Women who did not receive a whooping cough booster immunisation (Boostrix®) before 38 weeks of pregnancy can purchase the vaccine through their local doctor.

Show in archive
Archive Date: 

Capital and Coast free whooping cough boosters

Thursday, 15 November 2012

The whooping cough vaccine is available for family/whānau of infants less than one year of age who are already accessing specified immunisation services.

The vaccine, Boostrix®, is available through general practice (GPs).

The District Health Board (DHB) will pay for the vaccine. However, providers may charge the patient a small vaccine administration fee. Please ask your GP about any vaccine administration cost.

Who is eligible?

  • Only family/whānau of infants less than one year of age already receiving immunisations through the following services:
    • An outreach immunisation service
    • An open immunisation clinic
    • One of the following Very Low Cost Access primary health services:
Compass Primary Health Care Network Ora Toa PHO Well Health Trust
Waitangirua Health Centre Ora Toa - Cannons Creek Newton Union Health Service
Massey Student Services Trust Ora Toa - Takapuwahia Te Aro Health Centre
Victoria Student Health Centre Ora Toa - Mungavin Porirua Union and Community Health Service
Pacific Health Service Porirua Ora Toa - Poneke Evolve Wellington Youth Service
Hora Te Pai Health Services    



Show in archive
Archive Date: 

New packaging for privately purchased Boostrix®

Friday, 22 June 2012

GSK have changed the packaging for privately purchased Boostrix®. This will enable practice staff to distinguish between privaterly puchased stock and Ministry of Health funded stock from ProPharma.

GSK distributed a letter to health providers on 21 June 2012, please familiarise yourself with the new packaging.

Show in archive
Archive Date: 

Funded Boostrix® in pregnancy

Wednesday, 12 December 2012

PHARMAC have extended the availability of funded Boostrix® for pregnant women between 28-38 weeks gestation from 1 January 2013.

New Zealand is in the midst of a pertussis epidemic. PHARMAC recently sought feedback on a proposal to extend funded Boostrix® for pregnant women in addition to those aged 11 years as per the National Immunisation Schedule.

Considerations and commentary around this decision are available in the  PHARMAC media release.

Show in archive
Archive Date: 

Boostrix® packaging change for ProPharma stock

Thursday, 31 January 2013

The packaging for ProPharma supplied Boostrix® will be changing.

GSK have issued a letter to general practices outlining the changes. The appearance of the single dose packaging has already changed for privately purchased stock from Healthcare Logistics.

Show in archive
Archive Date: 



Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation to protect against diphtheria, tetanus and pertussis (whooping cough).

*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.

Boostrix® is licensed for use in children 10 years of age and over and adults as a booster vaccine. Boostrix® can be used, out of licensure in children from 7 years of age and adults, for one or all three doses of a primary course of tetanus and diphtheria vaccination, so as to provide protection from pertussis (whooping cough). There is no alternative vaccine that provides protection from pertussis available in New Zealand for this age group. 

When children are younger than the age to which the vaccine is licensed, and when the vaccine is used for a primary vaccination course, use will be outside of current licensure and parents/guardians/individuals must be fully informed of this. There are not expected to be any safety concerns for use in these circumstances.

What is the difference between Infanrix®-hexa, Infanrix®-IPV and Boostrix® vaccines?


The infant vaccine Infanrix®-hexa (DTaP-IPV-HepB/Hib) protects against six diseases (diphtheria, tetanus, whooping cough, polio, hepatitis B and Haemophilus influenzae type b (Hib) disease), while Infanrix®-IPV (DTaP-IPV) protects against the first four of these diseases. The adolescent and adult vaccine Boostrix® (Tdap) boosts protection against diphtheria, tetanus and acellular pertussis (whooping cough) but is sometimes used in a primary vaccine course.

The infant and adult vaccines contain different volumes of some active ingredients, or antigens. Infanrix®-hexa and Infanrix®-IPV have a higher volume of tetanus, diphtheria and acellular pertussis antigens, which are needed to stimulate a strong immune response. Boostrix® contains smaller doses of tetanus, diphtheria and pertussis antigens, the immune response to these invaders already exists, so the vaccine is only required to "remind" the immune response about how to respond. Local site reactions to the tetanus, diphtheria and acellular pertussis vaccines increase after the fourth dose, so the smaller dose of these components also helps to avoid these reactions in adolescents.

FAQ types: 
Subscribe to RSS - Boostrix